Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lethal Congenital Contracture Syndrome 2 × seribantumab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor Cancers 1 Lethal Congenital Contracture Syndrome 2 1 Head and Neck Neoplasms 1

Interventions

seribantumab 1 patritumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

Phase 1 Completed

44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡